Announcements
- uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease
- uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
- uniQure Announces 2023 Financial Results and Highlights Recent Company Progress
- uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
- uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease
- uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
- uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting
- uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs
- uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy
More ▼
Key statistics
On Friday, Uniqure NV (UQ1:BER) closed at 4.82, 18.95% above the 52 week low of 4.05 set on Apr 30, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.82 |
---|---|
High | 4.82 |
Low | 4.82 |
Bid | 4.91 |
Offer | 4.97 |
Previous close | 4.93 |
Average volume | 199.50 |
---|---|
Shares outstanding | 48.55m |
Free float | 46.47m |
P/E (TTM) | -- |
Market cap | 263.14m USD |
EPS (TTM) | -6.20 USD |
Data delayed at least 15 minutes, as of Jun 07 2024 07:05 BST.
More ▼